Your browser is no longer supported. Please, upgrade your browser.
ORIC ORIC Pharmaceuticals, Inc. daily Stock Chart
ORIC Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)- Insider Own0.40% Shs Outstand28.75M Perf Week-15.03%
Market Cap698.62M Forward P/E- EPS next Y-2.14 Insider Trans0.00% Shs Float16.21M Perf Month-23.82%
Income- PEG- EPS next Q-0.34 Inst Own59.90% Short Float15.46% Perf Quarter-
Sales- P/S- EPS this Y-25.80% Inst Trans- Short Ratio8.21 Perf Half Y-
Book/sh- P/B- EPS next Y11.90% ROA- Target Price42.75 Perf Year-
Cash/sh2.76 P/C8.80 EPS next 5Y- ROE- 52W Range23.50 - 40.67 Perf YTD-5.70%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-40.20% Beta-
Dividend %- Quick Ratio16.80 Sales past 5Y- Gross Margin- 52W Low3.49% ATR2.92
Employees57 Current Ratio16.80 Sales Q/Q- Oper. Margin- RSI (14)32.56 Volatility9.80% 9.76%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.13 Prev Close24.30
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume305.25K Price24.32
Recom1.60 SMA20-22.82% SMA50-23.17% SMA200-21.91% Volume3,313 Change0.08%
May-19-20Initiated JP Morgan Overweight $40
May-19-20Initiated Jefferies Buy $40
May-19-20Initiated Guggenheim Buy $45
May-19-20Initiated Citigroup Neutral $35
Jun-22-20 09:00AM  
Jun-09-20 04:15PM  
May-27-20 06:30AM  
May-26-20 06:30AM  
May-20-20 04:15PM  
Apr-28-20 04:30PM  
Apr-27-20 04:30PM  
Apr-23-20 08:56PM  
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.